<DOC>
	<DOC>NCT02217410</DOC>
	<brief_summary>The purpose of this study is to investigate the safety, tolerability, pharmacokinetics (PK) and potential for CFZ533 to replace calcineurin inhibitors (CNI), while providing a similar rate of acute rejection prophylaxis and renal function in a de novo renal transplant population receiving an allograft from standard criteria donors.</brief_summary>
	<brief_title>CCFZ533X2201 - PoC Study in de Novo Renal Transplantation</brief_title>
	<detailed_description />
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>Main Written informed consent must be obtained before any assessment is performed. Recipients of a kidney transplant from a heartbeating deceased, living unrelated or nonhuman leukocyte antigen (HLA) identical living related donor. Recipients of a kidney with a cold ischemia time (CIT) &lt; 30 hours. Main Recipients of an organ from a nonheart beating donor. ABO incompatible or complementdependent lymphocytotoxic (CDC) crossmatch positive transplant. Subjects receiving a second kidney allograft, unless the first allograft was lost due to surgical complication. Subjects at high immunological risk for rejection Subjects at risk for tuberculosis (TB) Subject with severe systemic infections, current or within the two weeks prior to randomization/enrollment. Any additional contraindication to the use of tacrolimus or mycophenolate mofetil according to the national labeling information of these products (see local product label). Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>renal, de novo,</keyword>
</DOC>